110 related articles for article (PubMed ID: 29531130)
1. Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.
Ring BZ; Murali R; Soslow RA; Bowtell DDL; Fereday S; deFazio A; Traficante N; Kennedy CJ; Brand A; Sharma R; Harnett P; Samimi G;
Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):680-688. PubMed ID: 29531130
[No Abstract] [Full Text] [Related]
2. TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.
Samimi G; Ring BZ; Ross DT; Seitz RS; Sutherland RL; O'Brien PM; Hacker NF; Huh WK
Cancer Epidemiol Biomarkers Prev; 2012 Feb; 21(2):273-9. PubMed ID: 22194527
[TBL] [Abstract][Full Text] [Related]
3. Angiosarcoma: a study of 98 cases with immunohistochemical evaluation of TLE3, a recently described marker of potential taxane responsiveness.
Shon W; Jenkins SM; Ross DT; Seitz RS; Beck RA; Ring BZ; Okuno SH; Gibson LE; Folpe AL
J Cutan Pathol; 2011 Dec; 38(12):961-6. PubMed ID: 22050093
[TBL] [Abstract][Full Text] [Related]
4. TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.
Bartlett JM; Nielsen TO; Gao D; Gelmon KA; Quintayo MA; Starczynski J; Han L; Burnell MJ; Levine MN; Chen BE; Shepherd LE; Chapman JW;
Br J Cancer; 2015 Sep; 113(5):722-8. PubMed ID: 26284338
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer.
Susini T; Berti B; Carriero C; Tavella K; Nori J; Vanzi E; Molino C; Di Tommaso M; Santini M; Saladino V; Bianchi S
Onco Targets Ther; 2014; 7():2111-20. PubMed ID: 25484594
[TBL] [Abstract][Full Text] [Related]
6. RNF6 Promotes Colorectal Cancer by Activating the Wnt/β-Catenin Pathway via Ubiquitination of TLE3.
Liu L; Zhang Y; Wong CC; Zhang J; Dong Y; Li X; Kang W; Chan FKL; Sung JJY; Yu J
Cancer Res; 2018 Apr; 78(8):1958-1971. PubMed ID: 29374067
[TBL] [Abstract][Full Text] [Related]
7. TLE3 as a candidate biomarker of response to taxane therapy.
Kulkarni SA; Hicks DG; Watroba NL; Murekeyisoni C; Hwang H; Khoury T; Beck RA; Ring BZ; Estopinal NC; Schreeder MT; Seitz RS; Ross DT
Breast Cancer Res; 2009; 11(2):R17. PubMed ID: 19309506
[TBL] [Abstract][Full Text] [Related]
8. Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
Kashiwagi S; Fukushima W; Asano Y; Goto W; Takada K; Noda S; Takashima T; Onoda N; Ohsawa M; Hirakawa K; Ohira M
BMC Cancer; 2017 Aug; 17(1):604. PubMed ID: 28859615
[TBL] [Abstract][Full Text] [Related]
9. Differential functions of TLE1 and TLE3 depending on a specific phosphorylation site.
Kornspan D; Smith Y; Nechushtan H
Biochem Biophys Res Commun; 2021 Mar; 545():164-170. PubMed ID: 33571907
[TBL] [Abstract][Full Text] [Related]
10. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
11. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
Leiser AL; Chi DS; Ishill NM; Tew WP
Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
[TBL] [Abstract][Full Text] [Related]
12. Expression of beta-tubulin isotypes in human primary ovarian carcinoma.
Ohishi Y; Oda Y; Basaki Y; Kobayashi H; Wake N; Kuwano M; Tsuneyoshi M
Gynecol Oncol; 2007 Jun; 105(3):586-92. PubMed ID: 17343904
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
Du J; Li B; Fang Y; Liu Y; Wang Y; Li J; Zhou W; Wang X
BMC Cancer; 2015 Jul; 15():536. PubMed ID: 26198101
[TBL] [Abstract][Full Text] [Related]
14. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S
Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.
Kavanagh J; Tresukosol D; Edwards C; Freedman R; Gonzalez de Leon C; Fishman A; Mante R; Hord M; Kudelka A
J Clin Oncol; 1995 Jul; 13(7):1584-8. PubMed ID: 7602347
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
18. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S
J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells.
Shu C; Zheng X; Wuhafu A; Cicka D; Doyle S; Niu Q; Fan D; Qian K; Ivanov AA; Du Y; Mo X; Fu H
Acta Pharmacol Sin; 2022 Sep; 43(9):2419-2428. PubMed ID: 35031699
[TBL] [Abstract][Full Text] [Related]
20. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D
Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
